EE507 Insulin Degludec/Insulin Aspart Versus Basal+Bolus Insulin Treatment (Insulin Glargine U100 & Insulin Aspart) in T2D in India: A Short-Term Cost-Effectiveness Analysis Based on the Step-By-Step Clinical Trial
| Autor: | Das, S, Modi, KD, Rao, PV, Pathan, MK, Revanna, M, Garcia Uranga, J |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S155-S155 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect